Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Commentary

Dendritic cell defects in patients with cancer: mechanisms and significance

Corrine Lenahan and David Avigan email

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA

author email corresponding author email

Breast Cancer Research 2006, 8:101doi:10.1186/bcr1375

Published: 5 January 2006


See related research by Pinzon-Charry et al. in this issue http://breast-cancer-research.com/content/8/1/R5

Abstract

Dendritic cells (DCs) are a complex network of antigen-presenting cells that have an essential role in the modulation of primary immunity. There has been increasing evidence that DCs isolated from patients with malignancy demonstrate functional deficiencies that inhibit the capacity to mount an effective anti-tumor response. In this issue of Breast Cancer Research, Pinzon-Charry and colleagues investigate one of the possible mechanisms by which tumors induce DC dysfunction to evade host immune surveillance. They demonstrate that DCs isolated from the circulation of patients with early-stage breast cancer exhibit increased rates of spontaneous apoptosis. In vitro studies suggest that a soluble factor secreted by breast cancer cells is responsible for this phenomenon. In contrast, ex vivo conditioning of DCs with CD-40 ligand and IL-12 was protective against tumor-induced apoptosis.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.